Prestige Consumer Healthcare Future Growth
Future criteria checks 1/6
Prestige Consumer Healthcare is forecast to grow earnings and revenue by 5.3% and 2.4% per annum respectively. EPS is expected to grow by 6.2% per annum. Return on equity is forecast to be 10.8% in 3 years.
Key information
5.3%
Earnings growth rate
6.2%
EPS growth rate
| Pharmaceuticals earnings growth | 19.9% |
| Revenue growth rate | 2.4% |
| Future return on equity | 10.8% |
| Analyst coverage | Good |
| Last updated | 28 Jan 2025 |
Recent future growth updates
Recent updates
Pinning Down Prestige Consumer Healthcare Inc.'s (NYSE:PBH) P/S Is Difficult Right Now
Jan 16
Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Could Be 45% Below Their Intrinsic Value Estimate
Dec 04We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Nov 03Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Popularity With Investors Is Under Threat From Overpricing
Sep 10Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Jul 16Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 1,182 | 242 | 271 | 288 | 3 |
| 3/31/2026 | 1,159 | 238 | 271 | 286 | 8 |
| 3/31/2025 | 1,132 | 224 | 256 | 271 | 8 |
| 9/30/2024 | 1,111 | 206 | 255 | 263 | N/A |
| 6/30/2024 | 1,113 | 205 | 246 | 256 | N/A |
| 3/31/2024 | 1,125 | 209 | 239 | 249 | N/A |
| 12/31/2023 | 1,134 | -81 | 232 | 241 | N/A |
| 9/30/2023 | 1,127 | -82 | 216 | 224 | N/A |
| 6/30/2023 | 1,130 | -84 | 211 | 220 | N/A |
| 3/31/2023 | 1,128 | -82 | 222 | 230 | N/A |
| 12/31/2022 | 1,109 | 210 | 225 | 234 | N/A |
| 9/30/2022 | 1,108 | 209 | 236 | 245 | N/A |
| 6/30/2022 | 1,095 | 203 | 240 | 249 | N/A |
| 3/31/2022 | 1,087 | 205 | 250 | 260 | N/A |
| 12/31/2021 | 1,058 | 189 | 245 | 256 | N/A |
| 9/30/2021 | 1,022 | 179 | 224 | 239 | N/A |
| 6/30/2021 | 983 | 179 | 209 | 230 | N/A |
| 3/31/2021 | 943 | 165 | 213 | 236 | N/A |
| 12/31/2020 | 957 | 166 | 207 | 233 | N/A |
| 9/30/2020 | 960 | 163 | 218 | 241 | N/A |
| 6/30/2020 | 960 | 152 | 222 | 240 | N/A |
| 3/31/2020 | 963 | 142 | 203 | 217 | N/A |
| 12/31/2019 | 953 | -34 | 199 | 212 | N/A |
| 9/30/2019 | 953 | -34 | 186 | 197 | N/A |
| 6/30/2019 | 954 | -36 | 176 | 186 | N/A |
| 3/31/2019 | 976 | -36 | 179 | 189 | N/A |
| 12/31/2018 | 991 | 64 | 183 | 193 | N/A |
| 9/30/2018 | 1,020 | 340 | 184 | 197 | N/A |
| 6/30/2018 | 1,039 | 340 | N/A | 212 | N/A |
| 3/31/2018 | 1,041 | 340 | N/A | 210 | N/A |
| 12/31/2017 | 1,026 | 390 | N/A | 163 | N/A |
| 9/30/2017 | 972 | 107 | N/A | 156 | N/A |
| 6/30/2017 | 929 | 109 | N/A | 151 | N/A |
| 3/31/2017 | 882 | 69 | N/A | 149 | N/A |
| 12/31/2016 | 849 | 72 | N/A | 179 | N/A |
| 9/30/2016 | 833 | 69 | N/A | 185 | N/A |
| 6/30/2016 | 824 | 68 | N/A | 182 | N/A |
| 3/31/2016 | 806 | 100 | N/A | 176 | N/A |
| 12/31/2015 | 788 | 110 | N/A | 189 | N/A |
| 9/30/2015 | 786 | 103 | N/A | 190 | N/A |
| 6/30/2015 | 761 | 88 | N/A | 170 | N/A |
| 3/31/2015 | 715 | 78 | N/A | 156 | N/A |
| 12/31/2014 | 668 | 70 | N/A | 135 | N/A |
| 9/30/2014 | 615 | 52 | N/A | 113 | N/A |
| 6/30/2014 | 601 | 69 | N/A | 118 | N/A |
| 3/31/2014 | 597 | 73 | N/A | 112 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PBH's forecast earnings growth (5.3% per year) is above the savings rate (2.6%).
Earnings vs Market: PBH's earnings (5.3% per year) are forecast to grow slower than the US market (15% per year).
High Growth Earnings: PBH's earnings are forecast to grow, but not significantly.
Revenue vs Market: PBH's revenue (2.4% per year) is forecast to grow slower than the US market (9% per year).
High Growth Revenue: PBH's revenue (2.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PBH's Return on Equity is forecast to be low in 3 years time (10.8%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/30 06:59 |
| End of Day Share Price | 2025/01/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Prestige Consumer Healthcare Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Olivia Tong Cheang | BofA Global Research |
| Linda Bolton-Weiser | B. Riley Securities, Inc. |
| Susan Anderson | Canaccord Genuity |